Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Arizona: - Cancer Center at Saint Joseph's — Phoenix, Arizona
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Arizona: - Cancer Center at Saint Joseph's — Phoenix, Arizona
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Arizona: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Mayo Clinic in Arizona — Scottsdale, Arizona
- University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Arizona: - The University of Arizona Cancer Center - North Campus ( Site 0073) — Tucson, Arizona
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Sites in Arizona: - Ironwood Cancer & Research Centers — Chandler, Arizona
- Ironwood Cancer & Research Centers — Gilbert, Arizona
- Palo Verde Hematology Oncology — Glendale, Arizona
- Ironwood Cancer & Research Centers — Glendale, Arizona
- Ironwood Cancer & Research Centers — Goodyear, Arizona
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in Arizona: - Honor Health Research Institute — Scottsdale, Arizona
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in Arizona: - Mayo Clinic- Phoenix — Phoenix, Arizona
Phase 3 Recruiting Academic/Other
1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radia…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06274047
Sites in Arizona: - Banner MD Anderson — Gilbert, Arizona
Phase 2 Recruiting Network
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05806515
Sites in Arizona: - Cancer Center at Saint Joseph's — Phoenix, Arizona
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Arizona: - Mayo Clinic — Phoenix, Arizona
- Honor Health — Scottsdale, Arizona
- Arizona Cancer Center at University of Arizona — Tucson, Arizona
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Arizona: - Research Site 111 — Tucson, Arizona
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Arizona: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Mayo Clinic — Phoenix, Arizona
- University of Arizona — Tucson, Arizona
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC …
Sponsor: Kyntra Bio
NCT ID: NCT06842498
Sites in Arizona: - Western Regional Medical Center - City of Hope Phoenix Goodyear — Goodyear, Arizona
- HonorHealth Research Institute — Scottsdale, Arizona
- The University of Arizona Cancer Center - North Campus — Tucson, Arizona
Phase 2 Recruiting Industry
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other…
Sponsor: Pfizer
NCT ID: NCT04606446
Sites in Arizona: - HonorHealth — Scottsdale, Arizona
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Arizona: - Mayo Clinic — Phoenix, Arizona
Phase 2 Recruiting Industry
Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation t…
Sponsor: Candel Therapeutics, Inc.
NCT ID: NCT07332000
Sites in Arizona: - Academic Urology and Urogynecology of Arizona — Peoria, Arizona
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.
Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.
NCT ID: NCT06609005
Sites in Arizona: - Honor Health — Scottsdale, Arizona
Phase 2 Recruiting Academic/Other
This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific membrane antigen (PSMA) and improving diagnostic imaging with PSMA positron emissi…
Sponsor: Mayo Clinic
NCT ID: NCT07025369
Sites in Arizona: - Mayo Clinic in Arizona — Scottsdale, Arizona
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Arizona: - Exelixis Clinical Site #67 — Phoenix, Arizona
- Exelixis Clinical Site #1 — Tucson, Arizona
Phase 1 Recruiting Industry
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered o…
Sponsor: MOMA Therapeutics
NCT ID: NCT06545942
Sites in Arizona: - Investigative Site #108 — Goodyear, Arizona
EARLY Phase 1 Recruiting Academic/Other
This early phase I is to find out how common vitamin D insufficiency is among African American patients with a history of prostate cancer that has not spread to other parts of the body (localized) or has spread to other places in the body …
Sponsor: Mayo Clinic
NCT ID: NCT05045066
Sites in Arizona: - Mayo Clinic in Arizona — Scottsdale, Arizona
Phase 1 Recruiting Industry
A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
Sponsor: SURGE Therapeutics
NCT ID: NCT06450106
Sites in Arizona: - Arizona Urology Specialists — Tucson, Arizona
NA Recruiting Industry
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
Sponsor: Axonics, Inc.
NCT ID: NCT06511141
Sites in Arizona: - Mayo Clinic — Scottsdale, Arizona
Recruiting Industry
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…
Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Arizona: - Research Site — Bullhead City, Arizona
- Research Site — Casa Grande, Arizona
Phase 4 Recruiting Industry
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x…
Sponsor: Guerbet
NCT ID: NCT04373564
Sites in Arizona: - Scottsdale Medical Imaging, LLC — Scottsdale, Arizona